NewsBenzingaコヤ・セラピューティクス、筋萎縮性側索硬化症の潜在的治療薬COYA 302を評価する第2/3相ALSTARS試験で、予定の120人全参加者の登録完了を発表 コヤ・セラピューティクス、筋萎縮性側索硬化症の潜在的治療薬COYA 302を評価する第2/3相ALSTARS試験で、予定の120人全参加者の登録完了を発表 Benzinga 2026.10.05 12:03 (GMT+0) Open on Benzinga Other news Wells Fargo Maintains Equal-Weight on Sonoco Products, Lowers Price Target to $53 Piper Sandler Maintains Neutral on WaFd, Lowers Price Target to $31 VinFast Says Real Estate Could Cover Its EV Cash Burn Wells Fargo Maintains Overweight on Silgan Hldgs, Lowers Price Target to $52 Piper Sandler Maintains Neutral on First Finl Bankshares, Lowers Price Target to $33 $1000 Invested In Extra Space Storage 20 Years Ago Would Be Worth This Much Today
